Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia Coyle JT; Balu D; Benneyworth M; Basu A; Roseman ADialogues Clin Neurosci 2010[]; 12 (3): 359-82All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative efficacy studies indicate marginal differences in efficacy of newer atypical antipsychotics and the older drugs, and little effects on negative and cognitive symptoms. This review integrates findings from postmortem, imaging, and drug-challenge studies to elucidate a corticolimbic "pathologic circuit" in schizophrenia that may be particularly relevant to the negative symptoms and cognitive impairments of schizophrenia. Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed.|Animals[MESH]|Antipsychotic Agents/classification/pharmacology/*therapeutic use[MESH]|Cognition Disorders/drug therapy/etiology[MESH]|Humans[MESH]|Models, Biological[MESH]|Neurotransmitter Agents/pharmacology/*therapeutic use[MESH]|Receptors, Cholinergic/classification/drug effects/metabolism[MESH]|Receptors, Dopamine/drug effects/*metabolism[MESH]|Receptors, GABA/drug effects/metabolism[MESH]|Receptors, N-Methyl-D-Aspartate/classification/drug effects/metabolism[MESH]|Schizophrenia/complications/*drug therapy[MESH] |